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1. INTRODUCTION {#gcc22743-sec-0001}
===============

Burkitt lymphoma (BL) is characterized by a translocation of the *MYC* oncogene that leads to the upregulation of *MYC* expression, cell growth and proliferation. It is well‐established that *MYC* translocation is not a sufficient genetic event to cause BL.[1](#gcc22743-bib-0001){ref-type="ref"}, [2](#gcc22743-bib-0002){ref-type="ref"}, [3](#gcc22743-bib-0003){ref-type="ref"}, [4](#gcc22743-bib-0004){ref-type="ref"} Next‐generation sequencing (NGS) has recently provided a comprehensive analysis of the landscape of additional genetic events that contribute to BL lymphomagenesis. Additional recurrent mutations are observed in the genes encoding TCF3 and its negative regulator, ID3, with up to 70% of tumors bearing mutations in one or both of the genes, suggesting that TCF3/ID3 play a key role in BL lymphomagenesis.[2](#gcc22743-bib-0002){ref-type="ref"}, [4](#gcc22743-bib-0004){ref-type="ref"} Furthermore, Epstein‐Barr virus (EBV), a ubiquitous oncogenic virus, is associated with B‐cell lymphomas, including BL and Hodgkin lymphoma.[5](#gcc22743-bib-0005){ref-type="ref"} The role of EBV in BL is still unclear, and it has been suggested that EBV‐positive (EBV+) and ‐negative cases might arise from different cells of origin. EBV+ BL may arise from late germinal center lymphoblast memory B‐cells and EBV− BL from an earlier stage of differentiation. Despite its aggressiveness, BL treated in first‐line by intensive combination chemotherapy with rituximab and central nervous system (CNS) preventative procedures has resulted in event‐free survival rates of 80% to 90%.[6](#gcc22743-bib-0006){ref-type="ref"} By contrast, refractory BL or relapsing (R/R) BL are almost always incurable as a result of the selection of highly chemoresistant clonally related cell populations. Conversely, a few BL recurrences arising from clonally distinct tumors have been reported and have been associated with a favorable outcome similar to that reported of first line treatment.[7](#gcc22743-bib-0007){ref-type="ref"}, [8](#gcc22743-bib-0008){ref-type="ref"}, [9](#gcc22743-bib-0009){ref-type="ref"}, [10](#gcc22743-bib-0010){ref-type="ref"}, [11](#gcc22743-bib-0011){ref-type="ref"} Here, we used an unusual case of recurrent but clonally distinct EBV+ BL to highlight the key genetic events that drive BL lymphomagenesis.

2. CASE REPORT {#gcc22743-sec-0002}
==============

An HIV‐negative Caucasian male individual initially presented in January 2015 at the age of 25 years with adenopathy and vena cava superior syndrome. No history of recurrent pulmonary infection/herpes virus infections or chronic inflammatory disease was reported. After lymph node biopsy, a diagnosis of BL with a typical immunophenotype was confirmed (BL1). Conventional cytogenetics showed that the tumor harbored the characteristic translocation t(8;22)(q24;q11) that juxtaposes the *MYC* and *IGL* loci with the loss of Y as an additional cytogenetic alteration (Supporting Information Figure [S1A](#gcc22743-supitem-0001){ref-type="supplementary-material"}). Staging indicated stage IV disease without any involvement of the bone marrow or CNS (Supporting Information Figure [S2A](#gcc22743-supitem-0001){ref-type="supplementary-material"}). The patient was treated with dose‐dense chemotherapy and rituximab, followed by autologous stem cell transplantation (ASCT) conditioned by BEAM (carmustine, etoposide, cytarabine, and melphalan)[12](#gcc22743-bib-0012){ref-type="ref"}. A complete remission (CR) was obtained. Two years later, the patient presented with facial paralysis and abdominal pain. PET scan showed multiple enlarged lymph nodes and a massive infiltration of the kidneys (Supporting Information Figure [S2B](#gcc22743-supitem-0001){ref-type="supplementary-material"}). Bone marrow biopsy displayed massive infiltration (around 30%) by typical BL cells, and the CNS was considered infiltrated. The diagnosis of Burkitt leukemia was confirmed (BL2). In this case, cytogenetics showed that the tumor harbored the characteristic translocation t(8;14)(q24;q32) that juxtaposes the *MYC* and *IGH* loci, with a short interstitial deletion of the long arm of chromosome 13 as an additional cytogenetic aberration (Supporting Information Figure [S1B](#gcc22743-supitem-0001){ref-type="supplementary-material"}). The main immunological features of BL1 and BL2, both EBV+/BCL2 neg/BCL6+, are summarized in Supporting Information Table [S1](#gcc22743-supitem-0001){ref-type="supplementary-material"} and representative histopathologic pictures provided in Supporting Information Figure [S3A/3B](#gcc22743-supitem-0001){ref-type="supplementary-material"}. The patient received two cycles of R‐HyperCVAD (rituximab, cyclophosphamide, dexamethasone, methotrexate, doxorubicin, vincristine, cytarabine) with intrathecal methotrexate injection. CR was obtained, and the patient underwent an allogeneic transplantation from an HLA‐identical sibling donor that was conditioned by a myeloablative regimen (cyclophosphamide and total‐body irradiation). To date, the patient is considered in CR, with a follow‐up of 18 months. No abnormal toxicities, including unusual prolonged pancytopenia or mucosal toxicity, were observed throughout the different therapeutic sequences.

3. MATERIAL AND METHODS {#gcc22743-sec-0003}
=======================

3.1. Routine procedures {#gcc22743-sec-0004}
-----------------------

Conventional cytogenetics, EBV expression analysis and immunohistochemistry were performed using routine procedures. CDR3 sequence and VDJ analyses were performed using routine BIOMED2 procedures.

3.2. Whole exome sequencing and targeted sequencing {#gcc22743-sec-0005}
---------------------------------------------------

WES was performed on the DNA of BL1 and BL2 tumor tissues and compared to germline DNA from PBMCs obtained at the time of initial diagnosis. Data analysis was conducted as fully described in a previous work.[13](#gcc22743-bib-0013){ref-type="ref"} Somatic variant calling was performed by VarScan, using germline DNA as a reference. Variant annotation was performed by GenerateReports software, as previously described.[14](#gcc22743-bib-0014){ref-type="ref"} To confirm some genetic variants, BL1 and BL2 tumor DNA was also analyzed using our in‐house dedicated lymphopanel, as previously reported.[15](#gcc22743-bib-0015){ref-type="ref"}

Copy number analysis was done using the copynumber Bioconductor package \[Nilsen G, Liestol K, Lingjaerde OC (2013); copynumber: Segmentation of single‐ and multi‐track copy number data by penalized least squares regression, R package version 1.20.0\].

The *FANCM* and *PI3KCD* gene mutations reported in the index case report were identified using primers in a cohort of 29 additional BL or high‐grade B‐cell lymphoma (HGBCL) cases harboring a *MYC* translocation detected either by conventional cytogenetics and/or FISH. The primer sequences are provided in Supporting Information.

To investigate functionally the Fanconi anemia (FA) pathway integrity, hypersensitivity to mitomycin C (MMC) and the profile of FancD2 monoubiquitination were analyzed in primary fibroblast cells obtained from skin biopsy.[16](#gcc22743-bib-0016){ref-type="ref"} The patient provided his consent for germline DNA sequencing.

4. RESULTS AND DISCUSSION {#gcc22743-sec-0006}
=========================

4.1. BL1 and BL2 are two clonally distinct diseases {#gcc22743-sec-0007}
---------------------------------------------------

To date, this report represents the most accurately described case of recurrent clonally distinct BL (see Supporting Information Table [S2](#gcc22743-supitem-0001){ref-type="supplementary-material"} for a summary of the previously published cases). This report provides the opportunity to highlight key molecular events that may contribute to BL oncogenesis. Conventional cytogenetics, VDJ/CDR3 sequence analysis and WES demonstrated without any ambiguity that BL1 and BL2 are two clonally distinct diseases that are sustained by distinct genetic events.

4.2. WES and targeted sequencing analysis demonstrated common and divergent alterations that drive BL oncogenesis {#gcc22743-sec-0008}
-----------------------------------------------------------------------------------------------------------------

In addition to *MYC* translocation, WES studies have identified genetic mutations implicating pathways involved in BL oncogenesis. These alterations involved cell cycle and proliferation (*ID3*, *MYC*, *TP53*, *RET*, *DDX3X*, *TCF3*, *GAB1*, *CCND3*, etc.), nucleosome remodeling (*ARID1A* and *SMARCA4*), focal adhesion (*GNA13*, *RHOA*, and *ROCK1*) or PI3K signaling (*PI3KR1*, *EIF4B*, and *FGFR2*).[3](#gcc22743-bib-0003){ref-type="ref"} We identified 64 acquired somatic variants in BL1 and 26 acquired variants in BL2. BL1 and BL2 harbored several mutations previously described that target the *MYC, TP53*, *SMARCA4, RHOA* and *ID3* genes (see Table [1](#gcc22743-tbl-0001){ref-type="table"} and Supporting Information). Of note, only *MYC* and *ID3* were mutated by distinct mutations in both BL1 and BL2. In BL1, the T73A *MYC* variant targets exon 2, whereas in BL2, the T8C variant was detected in exon 1. It is hypothesized that *MYC* mutations are a consequence of *MYC* translocation and somatic mutation processes under the control of Ig elements and may contribute to mRNA stability or MYC protein function. Because *ID3* mutations were observed in both BL1 and BL2, our observation reinforces the fact that these mutations represent a crucial step during BL oncogenesis. The BL2 variant is classified as a variant of uncertain significance. However, as previously reported, both variants occur in the highly conserved helix‐loop‐helix (HLH) functional domain of the protein, which is critical to its interactions with other HLH proteins.

###### 

List of acquired somatic mutations detected by whole exome sequencing in the Burkitt lymphoma (BL) cases. Genes are classified by alphabetic order

  Tumor   CHROM   Type       Gene       Exonic type         GenerateReports Class    SIFT score   Tumor variant frequency
  ------- ------- ---------- ---------- ------------------- ------------------------ ------------ -------------------------
  BL1     chr9    Exonic     ABCA1      Stopgain            Uncertain significance   --           48.96%
  BL1     chr11   Exonic     ADAMTS15   Nonsynonymous SNV   Likely pathogenic        0.001        33.33%
  BL1     chr19   Exonic     ADGRL1     Nonsynonymous SNV   Uncertain significance   0.177        42.13%
  BL1     chr17   Exonic     ALOX12B    Nonsynonymous SNV   Uncertain significance   1.0          35.56%
  BL1     chr17   Exonic     AOC3       Nonsynonymous SNV   Likely pathogenic        0.001        47.96%
  BL1     chr2    Exonic     BMP10      Nonsynonymous SNV   Likely pathogenic        0.0          50.3%
  BL1     chr20   Exonic     BTBD3      Nonsynonymous SNV   Likely pathogenic        0.003        45.22%
  BL1     chr4    Exonic     CASP6      Nonsynonymous SNV   Likely pathogenic        0.0          38.1%
  BL1     chr18   Exonic     CDH19      Nonsynonymous SNV   Likely pathogenic        0.001        40%
  BL1     chr9    Exonic     CDK5RAP2   Synonymous SNV      Uncertain significance                27.27%
  BL1     chr1    Exonic     CLCA4      Nonsynonymous SNV   Uncertain significance   0.267        37.5%
  BL1     chr2    Exonic     CNOT11     Nonsynonymous SNV   Likely pathogenic        0.002        44.05%
  BL1     chr13   Exonic     COL4A1     Nonsynonymous SNV   Uncertain significance   0.313        41.75%
  BL1     chr11   Exonic     DNHD1      Nonsynonymous SNV   Uncertain significance   0.729        20.2%
  BL1     chr9    Exonic     FAM157B    Nonsynonymous SNV   Uncertain significance                16.67%
  BL1     chr2    Exonic     FARSB      Nonsynonymous SNV   Likely pathogenic        0.0          41.1%
  BL1     chr13   Exonic     FOXO1      Nonsynonymous SNV   Likely pathogenic        0.0          42.19%
  BL1     chr5    Exonic     FYB        Nonsynonymous SNV   Uncertain significance   0.804        61.29%
  BL1     chr11   Exonic     GAB2       Nonsynonymous SNV   Uncertain significance   0.153        45.79%
  BL1     chr6    Exonic     GFRAL      Nonsynonymous SNV   Uncertain significance   0.0          45.92%
  BL1     chr3    Exonic     GNAI2      Nonsynonymous SNV   Likely pathogenic        0.005        38.59%
  BL1     chr15   Exonic     GOLGA6L3   Nonsynonymous SNV   Uncertain significance                23.08%
  BL1     chr3    Exonic     GRIP2      Unknown             Likely pathogenic        --           37.78%
  BL1     chr1    Exonic     HMCN1      Nonsynonymous SNV   Uncertain significance   0.592        38.98%
  BL1     chr1    Exonic     HMCN1      Nonsynonymous SNV   Likely pathogenic        0.026        43.44%
  BL1     chr1    Exonic     ID3        Nonsynonymous SNV   Likely pathogenic        0.0          39.59%
  BL1     chr19   Exonic     LMTK3      Nonsynonymous SNV   Likely pathogenic        0.0          20%
  BL1     chr19   Exonic     MED29      Nonsynonymous SNV   Uncertain significance   0.094        42.03%
  BL1     chr2    Exonic     MEMO1      Nonsynonymous SNV   Uncertain significance   0.307        23.08%
  BL1     chr2    Exonic     MEMO1      Nonsynonymous SNV   Uncertain significance   0.076        37.5%
  BL1     chr8    Exonic     MYC        Nonsynonymous SNV   Likely pathogenic        0.037        41.95%
  BL1     chr1    Exonic     NBPF10     Nonsynonymous SNV   Uncertain significance   --           18.75%
  BL1     chr1    Exonic     NPR1       Nonsynonymous SNV   Likely pathogenic        0.001        38.89%
  BL1     chr22   Exonic     PHF21B     Nonsynonymous SNV   Uncertain significance   0.033        44.62%
  BL1     chr1    Exonic     PIK3CD     Nonsynonymous SNV   Likely pathogenic        0.002        48%
  BL1     chr8    Exonic     PPP2R2A    Nonsynonymous SNV   Likely pathogenic        0.006        41.14%
  BL1     chr4    Exonic     PPP2R2C    Nonsynonymous SNV   Uncertain significance   0.18         43.63%
  BL1     chr1    Exonic     PRAMEF22   Nonsynonymous SNV   Uncertain significance                27.27%
  BL1     chr4    Splicing   PRIMPOL    NA                  Likely pathogenic        --           16.67%
  BL1     chr7    Exonic     PTPRZ1     Nonsynonymous SNV   Likely pathogenic        0.029        41.46%
  BL1     chr1    Exonic     RAP1GAP    Nonsynonymous SNV   Uncertain significance   0.142        38.41%
  BL1     chr3    Exonic     RHOA       Nonsynonymous SNV   Uncertain significance   0.118        35.64%
  BL1     chr3    Exonic     RHOA       Nonsynonymous SNV   Likely pathogenic        0.002        33.91%
  BL1     chr5    Splicing   RNF145     NA                  Likely pathogenic        --           50%
  BL1     chr7    Exonic     RSPH10B    Nonsynonymous SNV   Likely pathogenic        0.031        18.18%
  BL1     chr7    Exonic     SEMA3C     Nonsynonymous SNV   Likely pathogenic        0.004        35.71%
  BL1     chr15   Exonic     SIN3A      Nonsynonymous SNV   Likely pathogenic        0.0          44.81%
  BL1     chr15   Exonic     SIN3A      Nonsynonymous SNV   Likely pathogenic        0.0          44.26%
  BL1     chr19   Exonic     SMARCA4    Nonsynonymous SNV   Likely pathogenic        0.0          49.11%
  BL1     chr13   Exonic     TBC1D4     Stopgain            Likely pathogenic        --           51.29%
  BL1     chr13   Exonic     TBC1D4     Stopgain            Uncertain significance   --           52.42%
  BL1     chrX    Exonic     TENM1      Nonsynonymous SNV   Likely pathogenic        0.0          85.9%
  BL1     chr15   Exonic     TLN2       Nonsynonymous SNV   Uncertain significance   0.291        42.96%
  BL1     chr17   Exonic     TP53       Nonsynonymous SNV   Likely pathogenic        0.0          47.2%
  BL1     chr18   Exonic     TRAPPC8    Nonsynonymous SNV   Uncertain significance   0.059        43.85%
  BL1     chr13   Exonic     TRPC4      Nonsynonymous SNV   Uncertain significance   0.382        47%
  BL1     chr15   Splicing   TRPM7      NA                  Likely pathogenic        --           44.26%
  BL1     chr11   Exonic     TUT1       Nonsynonymous SNV   Uncertain significance   1.0          48.63%
  BL1     chr1    Exonic     USH2A      Nonsynonymous SNV   Uncertain significance   0.259        43.62%
  BL1     chr15   Exonic     WDR72      Nonsynonymous SNV   Uncertain significance   0.091        39.73%
  BL1     chr2    Exonic     XIRP2      Nonsynonymous SNV   Uncertain significance   0.014        42.31%
  BL1     chr19   Exonic     ZNF555     Stopgain            Uncertain significance   --           47.37%
  BL1     chr2    Exonic     ZSWIM2     Nonsynonymous SNV   Likely pathogenic        0.018        49.09%
  BL1     chr6    Exonic     MOXD1      Nonsynonymous SNV   Likely pathogenic        0.002        40.54%
  BL2     chr1    Exonic     IGFN1      Nonsynonymous SNV   Likely pathogenic        0.009        18.39%
  BL2     chr6    Exonic     ADGB       Nonsynonymous SNV   Likely pathogenic        0.027        20%
  BL2     chr5    Exonic     ANKRD31    Nonsynonymous SNV   Likely pathogenic        0.003        18.18%
  BL2     chr12   Exonic     ANO6       Nonsynonymous SNV   Uncertain significance   1.0          16.67%
  BL2     chr10   Exonic     ARMC4      Nonsynonymous SNV   Uncertain significance   0.1          25%
  BL2     chr11   Exonic     C11orf74   Nonsynonymous SNV   Uncertain significance   0.031        16.95%
  BL2     chr22   Exonic     CDC42EP1   Nonsynonymous SNV   Uncertain significance   0.006        18.18%
  BL2     chr19   Exonic     CIC        Nonsynonymous SNV   Likely pathogenic        --           16.67%
  BL2     chrX    Exonic     CYBB       Nonsynonymous SNV   Uncertain significance   0.167        18.18%
  BL2     chr1    Exonic     DNAH14     Nonsynonymous SNV   Likely pathogenic        0.0          20%
  BL2     chr9    Exonic     FAM102A    Nonsynonymous SNV   Uncertain significance   0.089        31.63%
  BL2     chr1    Exonic     ID3        Stopgain            Uncertain significance   --           39.6%
  BL2     chr22   Exonic     IGLL5      Nonsynonymous SNV   Uncertain significance                31.25%
  BL2     chr1    Exonic     KIAA0754   Nonsynonymous SNV   Uncertain significance   --           16.67%
  BL2     chr11   Exonic     KRTAP5‐4   Nonsynonymous SNV   Uncertain significance   0.03         25.81%
  BL2     chr11   Exonic     MCAM       Nonsynonymous SNV   Uncertain significance   0.181        21.43%
  BL2     chr3    Exonic     MUC20      Nonsynonymous SNV   Uncertain significance   0.0          16.67%
  BL2     chr8    Exonic     MYC        Nonsynonymous SNV   Likely pathogenic        0.001        20%
  BL2     chr14   Exonic     OR4E1      Nonsynonymous SNV   Uncertain significance                20%
  BL2     chr7    Exonic     PLXNA4     Stopgain            Likely pathogenic        --           19.67%
  BL2     chrX    Exonic     RBMX2      Nonsynonymous SNV   Uncertain significance   0.327        22.22%
  BL2     chr8    Exonic     SPATC1     Nonsynonymous SNV   Uncertain significance   0.006        19.84%
  BL2     chr6    Exonic     TRDN       Nonsynonymous SNV   Uncertain significance   0.007        18.18%
  BL2     chr6    Exonic     TRDN       Nonsynonymous SNV   Uncertain significance   0.268        27.27%
  BL2     chr7    Exonic     VGF        Nonsynonymous SNV   Uncertain significance   0.865        17.65%
  BL2     chr4    Exonic     ZFP42      Nonsynonymous SNV   Uncertain significance   0.599        16.04%

Mutations are thought to alter the tumor suppressor ability of ID3, which is also a direct transcriptional target of *MYC*. Targeted sequencing using our in‐house lymphopanel confirmed *ID3* mutations with similar variant allele frequencies (44.26% in BL1 \[p.I69S\] and 46.7% in BL2 \[p.Q71X\]). Several mutations targeting genes involved in the PI3K signaling pathway, including *PIK3R1*, *GAB1*, *FGFR2*, and *EIF4B*, have been previously reported and suggest a cooperative role between MYC and the deregulation of PI3K signaling.[3](#gcc22743-bib-0003){ref-type="ref"}

To the best of our knowledge, we report here for the first time a heterozygous acquired mutation E1021K in *PIK3CD*, detected in BL1 (Table [1](#gcc22743-tbl-0001){ref-type="table"}), thus increasing the spectrum of somatic mutations altering the PI3K signaling pathway in BL. Interestingly, this gain‐of‐function (GOF) mutation is known to be associated with activated phosphoinositide 3‐kinase delta syndrome (APDS).[17](#gcc22743-bib-0017){ref-type="ref"} This inherited disorder, resulting from GOF mutations in *PIK3CD*, the gene encoding the p110δ catalytic subunit of phosphoinositide 3‐kinase (PI3KCδ), includes recurrent pulmonary infections (98%), nonneoplastic lymphoproliferations (75%), herpesvirus infections (49%) and autoinflammatory diseases (34%).[17](#gcc22743-bib-0017){ref-type="ref"} Of note, four heterozygous GOF *PIK3CD* mutations (E1021K, N334K, E525K, and C416R) have been described, with E1021K being the most common. In the largest APDS cohort reported by Coulter and colleagues[17](#gcc22743-bib-0017){ref-type="ref"}, seven (13%) patients developed lymphoma between the ages of 18 months and 27 years. The cases were of various B‐cell histology, and two cases were considered EBV‐positive. To date, no BL case has been reported. Of note, in a cohort of 29 BL/HGBCL cases, we failed to detect any mutations targeting the PI3KCD kinase domain (Supporting Information). In addition, we identified several mutations that may contribute to lymphomagenesis or aggressiveness of the disease, including *SIN3A* (Sin3a causes the deacetylation of the MYC protein to directly repress MYC activity), *FOXO1*, *FYB*, and *GNAI2* (Table [1](#gcc22743-tbl-0001){ref-type="table"})[3](#gcc22743-bib-0003){ref-type="ref"}. Copy number variations (CNVs) were also analyzed and compared between BL1 and BL2. The list of CNVs is available in Supporting Information. In BL1, 133 CNV (53 losses, 80 gains) were identified (Supporting Information Table [S5](#gcc22743-supitem-0001){ref-type="supplementary-material"}). CNV were mainly related to Immunoglobulin loci rearrangements and chromosome Y loss. No CNV was associated with somatic mutation of the second allele. Only seven CNV were retained in BL2, targeting genes of uncertain relevance in this setting. No CNV was shared by BL1 and BL2. This result suggests that *MYC* rearrangements and some mutations (*ID3*) are the key‐genetic events of the disease. Discrepancies between CNV detected by WES and conventional cytogenetics can be mostly explained by the sensibility of the two approaches. The Del (13)(q13q14) detected by conventional cytogenetics in BL2 and confirmed by FISH (data not shown) was not detected by the algorithm used for WES CNV analysis, reflecting most likely a percentage of tumor cells under the threshold of CNV detection sensibility.

4.3. Clinical and potential therapeutic relevance {#gcc22743-sec-0009}
-------------------------------------------------

Our case report confirms the crucial role of the PI3K/Akt/mTOR pathway in BL and the spectrum of mutations that contributes to its deregulation. Importantly, the PI3KCD inhibitor idelalisib has been investigated in a panel of BL cell lines, including cell lines that exhibit a high degree of resistance to both chemotherapy and anti‐CD20 immunotherapy, and demonstrate preclinical activity.[18](#gcc22743-bib-0018){ref-type="ref"} Because PI3K/Akt is activated in EBV‐associated lymphoma by inducing BCR signaling, the mutation reported in an EBV+ BL suggests a synergistic effect able to alter this pathway. An oral dual inhibitor of PI3Kγ and PIK3CD (PI3Kδ), duvelisib, induces both apoptosis and cell cycle arrest in EBV‐positive and ‐negative B cell lines and reduces the expression of EBV lytic genes (BZLF1 and gp350/220) in EBV‐positive B cell lines.[19](#gcc22743-bib-0019){ref-type="ref"} Our current observation therefore highlights new therapeutic opportunities in BL. Furthermore, a recently developed transgenic mouse model shows that the concurrent activation of both Myc and PI3K leads to lymphoid tumors that morphologically and genetically appear BL‐like, suggesting that the coordination of overexpression of *Myc* and activation of PI3K may contribute to the development of BL and represent key synergistic events during lymphomagenesis.[20](#gcc22743-bib-0020){ref-type="ref"}

4.4. Constitutional genetic background that may contribute to BL emergence {#gcc22743-sec-0010}
--------------------------------------------------------------------------

Because BL1 and BL2 were both EBV+ and EBV infection is considered as a risk factor for developing BL, we tried to detect some alterations in target genes that are involved in EBV immune response and favor EBV‐associated lymphoproliferative disorders (LPDs). Among these alterations are *SH2D1A (SAP), XIAP, ITK, MAGT1, CD27, CD70, CTPS1, RASGRP1,* and *CORO1A* deficiencies.[21](#gcc22743-bib-0021){ref-type="ref"} None of these genes were found to be altered in BL1, BL2 or germline DNA, suggesting that an EBV immune response deficiency involving these genes cannot be considered responsible for this unusual phenotype.

We then sought more specifically to identify alterations in genes involved in DNA repair. We identified a heterozygous stop‐gain mutation (c.5791C\>T; p.Arg1931\*) in the *FANCM* gene. This mutation was also detected in the patient\'s sister, demonstrating that the mutation is inherited (see pedigree in Supporting Information Figure [S4](#gcc22743-supitem-0001){ref-type="supplementary-material"}). At the resolution level of a WES approach we did not detect a *FANCM copy loss*. *FANCM* was identified in 2005 as a member of the FA core complex. Its product FANCM plays an important role in the FA pathway involved in DNA damage responses and repair.[22](#gcc22743-bib-0022){ref-type="ref"} Interestingly, it has been demonstrated that the *FANCM* c.5791C\>T nonsense mutation induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.[23](#gcc22743-bib-0023){ref-type="ref"}, [24](#gcc22743-bib-0024){ref-type="ref"} The mutation causes an out‐of‐frame deletion of exon 22 due to the creation of a binding site for the pre‐mRNA processing protein hnRNP A1.[24](#gcc22743-bib-0024){ref-type="ref"}

To verify the functional consequences of the c.5791C\>T mutation, we performed reverse transcriptase‐polymerase chain reaction (RT‐PCR) with patient PBMC RNA. We confirmed that this mutation was also related to aberrant splicing (Supporting Information Figure [S4](#gcc22743-supitem-0001){ref-type="supplementary-material"}) with the expression of the Δ22 allele. A qRT‐PCR assay indicated that the Δ22 and wild‐type alleles were equally expressed in the BL tumor cells (Supporting Information Figure [S4](#gcc22743-supitem-0001){ref-type="supplementary-material"}). Of note, in an additional cohort of 29 BL cases with available tumor DNA, we did not find the *FANCM* c.5791C\>T nonsense mutation (Supporting Information Table [S3](#gcc22743-supitem-0001){ref-type="supplementary-material"}). However we cannot rule out other mutations targeting this gene. Biallelic inactivating mutations in *FANCM* favor early‐onset cancer, although the patients typically do not present congenital malformations or hematological disorder suggestive of FA.[25](#gcc22743-bib-0025){ref-type="ref"} Importantly, our patient did not develop unusual toxicities during genotoxic treatments, including radiotherapy, suggesting the absence of an underlying FA condition. Consistently, primary fibroblast cells from the patients did not exhibit hypersensitivity to cross‐linking agent MMC, excluding the FA diagnosis. Overall the role of the heterozygous truncating *FANCM* mutation~~s~~ in the emergence of the two unrelated BL and MYC translocation is unclear. While we ruled out a bona fide Fanconi anemia, *FANCM* heterozygous variants have been associated to weak cancer predisposition by GWAS studies.[26](#gcc22743-bib-0026){ref-type="ref"} Heterozygous loss of function mutations within the *FANCM* gene, including the c.5791C\>T variant, were also significantly associated with familial breast cancer risk, with an overall odds ratio (OR) of 2.05.[27](#gcc22743-bib-0027){ref-type="ref"} Despite a quantitative difference, the pattern of somatic mutations observed in BL1 and BL2 did not differ significantly, suggesting that BL1 and BL2 were sustained by a similar mutational process rather than arising as a consequence of a treatment side effect (Supporting Information Figure [S5](#gcc22743-supitem-0001){ref-type="supplementary-material"}). To conclude, this unusual observation highlights the key events that lead to the emergence of genetically distinct BL types (Figure [1](#gcc22743-fig-0001){ref-type="fig"}). The role of the inherited heterozygous truncating c.5791C\>T *FANCM* mutation is uncertain and could be purely coincidental. *ID3* mutations are shared by the two clonally distinct diseases and represent a key secondary genetic event following *MYC* translocation. The *PI3KCD* mutation expands the spectrum of mutations targeting the PI3K pathway and offers potential therapeutic opportunities in BL.

![Schematic view of the different steps of the lymphomagenesis. ![](GCC-58-595-g002.jpg "image") Polyclonal B‐cell infection by EBV. ![](GCC-58-595-g003.jpg "image") During EBV+ B‐cell maturation through germinal center transit, AID is expressed and favors *MYC/IG* loci (IGH or IGL) translocation and somatic mutations. ![](GCC-58-595-g004.jpg "image") As *MYC* rearrangement and EBV infection, the *ID3* gene is targeted by a somatic mutational process shared by the two clonally recurrent Burkitt lymphoma (BL) and act synergistically with MYC \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](GCC-58-595-g001){#gcc22743-fig-0001}
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